Associated Lab Members
Dr. Law graduated from the University of Manchester (UK) in 2002. After serving as a research scientist at Advanced Biomedical, he transitioned to a postdoctoral research fellowship at Massachusetts General Hospital/Harvard Medical School. In 2013, he joined Radiology Department at Weill Cornell Medicine as a faculty member. His research centers on creating peptide-based nanomaterials for precision drug delivery. Dr. Law utilizes multimodal imaging techniques (PET/CT/fluorescence) to study the pharmacokinetics and biodistribution of drugs and contrast agents. With a keen interest in innovative cancer treatments, he is actively developing novel therapeutics. His research is supported, in part, by the National Cancer Institute and the US Department of Defense.
Areas of Specialization: Combinatorial Therapeutics (peptide-based, biologics, chemotherapy)/ Drug Screening and Delivery/Translational X-Ray/CT/PET Development
Applications: Applied Pharmacokinetic and Biodistribution Research/Cancer Diagnosis and Treatment (brain, breast, bladder)
Dr. Bhattarai earned his doctorate in Medical Physics from the University of Eastern Finland (2020). During his doctoral training, he developed an innovative dual-energy CT technique for diagnosing post-traumatic osteoarthritis. He then pursued a post-doctoral fellowship at the University of Hong Kong, focusing on advancing multi-spectral photon-counting CT in diverse medical applications. With a dedicated career in medical imaging and a passion for functional imaging techniques, he strives to enhance diagnostic capabilities. As a post-doctoral associate, Dr. Bhattarai is advancing PET/CT/X-ray imaging to detect and monitor the disease progression of local and metastatic breast and bladder cancers. ORCID-ID(0000-0003-3713-1349), LinkedIn (Abhisek Bhattarai).
Dr. Geromichalou obtained her MSc in organic chemistry from Aristotle University in 2013. After completing her Ph.D. at Kapodistrian University of Athens in 2019, she served as a Research Scientist in a private Greek Biotech company, specializing in the development of diagnostic reagents, particularly in clinical chemistry and immunochemistry. In 2022, she joined Dr. Law's lab at the Radiology Department of Weill Cornell Medicine as a Postdoctoral Research Scientist. Her current focus is on utilizing imaging techniques to explore innovative therapeutic strategies for treating bladder cancer.
Dr. Silveria earned a bachelor's degree in biotechnology from the Federal University of Pelotas (UFPel) in 2015. Following this, she relocated to Ribeirao Preto and pursued a master’s degree at the Ribeirao Preto Medical School (FMRP) in 2018. Specializing in virology, Dr. Silveria researched the Zika virus. She is also actively engaged in engineering chimeric CAR-T cells against multiple myeloma. Immersed in academia, she completed her doctoral degree at the same institute in 2023. Dr. Silveria is poised to advance immunotherapies for urothelial carcinoma her at Weill Cornell Medicine, continuing an impactful journey in biotechnology and medical research.
Dr. Voura has a BS in Chemistry and an MSc in Organic Chemistry. She obtained her PhD in organic synthesis at Aristotle University of Thessaloniki in 2022, where she designed and synthesized small molecules, natural products, and PROTACs targeting MARK4 kinase. During her studies, Dr. Voura became interested in drug delivery systems for cancer treatment. In 2023, She joined as a Postdoctoral Associate in Law’s lab, focusing on developing new drug delivery systems using peptides targeting biomarkers for cancer treatment.
National Institute of Health (NCI) 07/03/2023-06/30/2028
Title: A urinary drug disposing approach for treatment of bladder cancer
National Institute of Health (NCI) 04/01/2023-03/30/2027
Title: Customized nanofibers with preferential lung-targeting properties of treating pulmonary tumors
National Institute of Health (NCI) 07/03/2018-06/30/2024
Title: A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment
The objective is to develop a platform to overcome multiple barriers in tumor-specific delivery.
National Institute of Health (NCI) 07/01/2017-06/30/2019
Title: Investigate peptide-based nanofiber as a multiplexed delivery system to metastatic breast tumors
Funding Source: Department of Defense 09/01/2017-08/30/2020
Title: Multifunctional nanofiber for convection-enhanced delivery of theranostics to diffuse intrinsic pontine glioma
09/01/2016-08/31/2018
Funding Source: Alex’s Lemonade Stand Foundation
Title: Image guided diffuse intrinsic pontine glioma drug delivery and design
The overall goal of this project is to combine advanced materials and neurosurgical techniques to develop new methods for effectively treating DIPG
To improve the treatment outcome, multiple drugs of distinctive mechanism but complementary anticancer activities are often used to enhance the antitumor efficacy and minimize the risk of acquiring drug resistance. Specifically, we investigate the synergistic effects of drug combinations, with the aim of developing new therapeutic...
Most bladder cancer (BC) patients are diagnosed at an early stage. The standard treatment involves surgically removing tumors, followed by intravesical immunotherapy (Bacillus Calmette-Guerin) or chemotherapy (ITC) to eradicate any residual cancer cells. However, current ITC methods are limited, with incomplete treatment, poor patient...
Among all pediatric cancers, DIPG stands out as the most aggressive. Focal radiotherapy only extends patient survival for a few months, and chemotherapy proves ineffective as DIPG inherently resists most chemotherapeutics. Moreover, the blood-brain barrier (BBB) naturally restricts many drugs from reaching the brain tumor...
The drawbacks of nanoparticles include poor tissue extravasation, incomplete drug release, and off-targeted delivery to the reticuloendothelial system and organs. In addressing these challenges, we have developed a new nanomaterial “nanofiber platform (NFP)” with unique dimensions (0.5 x 5 x 100 nm), setting it apart from other nanoparticles....
